Shanghai Cancer Center and Shanghai Medical College, Fudan University, Shanghai, China. wozhangsheng@hotmail.com. Shanghai Cancer Center and Shanghai Medical College, Fudan University, Shanghai, China. Department of Clinical Biochemistry, School of Public Health Taishan Medical University, Taian, China.
Pneumonitis, a rare but potentially life-threatening adverse event in cancer patients receiving programmed death 1 or programmed death ligand 1 inhibitors, has been reported in case reports, clinical trials, and retrospective studies. We performed a systematic review and meta-analysis to calculate the RR of pneumonitis associated with the use of PD-1/L1 inhibitors in randomized clinical trials . We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, trial registers, c...更多
Pneumonitis, a rare but potentially life-threatening adverse event in cancer patients receiving programmed death 1 or programmed death ligand 1 inhibitors, has been reported in case reports, clinical trials, and retrospective studies. We performed a systematic review and meta-analysis to calculate the RR of pneumonitis associated with the use of PD-1/L1 inhibitors in randomized clinical trials . We searched MEDLINE, Embase, the Cochrane Central Register of Controlled Trials, trial registers, conference proceedings, review articles, and reference lists of trial publications for all relevant RCTs comparing PD-1/L1 inhibitors to control with available data on pneumonitis. The pooled incidence, RR, and 95% confidence intervals were calculated using fixed effects or random effects model according to the heterogeneity of included trials. Twelve RCTs were eligible for the meta-analysis, yielding a total of 5,775 patients included in trials evaluating a PD-1 inhibitor; no eligible trials evaluated a PD-L1 inhibitor. The pooled incidence of all-grade pneumonitis for patients treated with PD-1 inhibitors was 3.2% , and that of high-grade pneumonitis was 1.1% . The RR of all-grade and high-grade pneumonitis was 4.36 and 2.86 , respectively. In a sensitivity analysis, PD-1 inhibitors were also associated with significantly increased risk of pneumonitis per person-month . PD-1 inhibitors were associated with a significant increase of all-grade and high-grade pneumonitis both per treatment episode and per person-month. Mol Cancer Ther; 16; 1588-95.收起
